U.S. Stock Market Midday Update
Fate Therapeutics rose 23.61%. Based on recent key news:
<ol>
<li>
On May 5, Fate Therapeutics was selected for the U.S. FDA's Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to support the manufacturing readiness of FT819. This selection boosted market confidence in the company's future development, driving the stock price up. Source: Reuters
</li>
<li>
On May 4, HC Wainwright &amp; Co. maintained a buy rating on Fate Therapeutics and raised the target price from $5 to $7. The analysts' positive rating and target price increase enhanced investor confidence, leading to a rise in the stock price. Source: Reuters
</li>
<li>
On May 4, Fate Therapeutics announced three presentations on ready-to-use CAR T cell therapies related to cancer and autoimmune diseases at the 2026 ASGCT annual meeting. These presentations highlighted the company's progress in innovative therapies, further driving the stock price up. Source: Reuters The biotechnology industry has recently performed strongly, with significant capital inflows.
</li>
</ol>
Stocks with High Trading Volume in the Industry
Cellectis rose 20.39%. Based on recent key news:
<ol>
<li>
On May 5, Cellectis announced that its heart disease drug significantly improved symptoms of hereditary heart disease in a late-stage trial. The drug achieved its primary endpoint in patients with non-obstructive hypertrophic cardiomyopathy, driving the stock price up.
</li>
<li>
On May 5, Cellectis' heart disease drug met dual primary endpoints in the pivotal ACACIA-HCM Phase 3 clinical trial, with no new safety signals found, further enhancing market confidence and leading to a substantial rise in the stock price.
</li>
<li>
On May 4, news of company executives selling shares did not significantly impact the stock price, as the market's positive reaction to the drug trial results dominated. The biotechnology industry has recently performed strongly, with significant capital inflows.
</li>
</ol>
Forte Pharmaceuticals fell 1.80%. Based on recent news:
<ol>
<li>
On May 4, Forte Pharmaceuticals released its first-quarter financial report, with adjusted earnings per share of $4.47, exceeding analysts' expectations of $4.19, but total revenue slightly fell short of expectations, leading to a decline in the stock price. The report showed the company's first-quarter revenue was $2.99 billion, below analysts' expectations of $3.03 billion.
</li>
<li>
On May 4, Forte Pharmaceuticals announced the termination of the Phase 1/2 study of the inhaled cystic fibrosis treatment VX-522 developed in collaboration with Moderna due to ongoing issues with drug tolerability, further putting pressure on the stock price.
</li>
<li>
On May 4, Forte Pharmaceuticals maintained its full-year revenue forecast between $12.95 billion and $13.1 billion. Despite the first-quarter performance falling short of expectations, the company remains optimistic about its full-year performance. The pharmaceutical industry overall is performing steadily, with increased R&amp;D investment
Cellectar Biosciences rose 16.19%. Based on recent key news:
</li>
<li>
On May 5, Cellectar Biosciences reached a financing agreement with institutional investors and management. The agreement includes approximately $35 million in upfront funding and up to $105 million in milestone securities. The financing structure consists of a registered direct offering of common stock and a concurrent private placement. This move aims to support the development of its targeted tumor treatment pipeline, driving the stock price up by 51.6%. Source: GlobeNewswire
</li>
<li>
No other significant news recently.
</li>
<li>
No other significant news recently. The biotechnology industry is active in financing activities, with high market attention.
</li>
</ol>
Stocks ranked at the top of the industry market capitalization
AbbVie fell 0.62%. Based on recent news,
<ol>
<li>
On May 5, AbbVie presented new long-term data at the 2026 Digestive Disease Week, enhancing the treatment standards for inflammatory bowel disease. This news boosted market confidence in the company's future growth but did not immediately reflect in the stock price.
</li>
<li>
On May 4, AbbVie announced that its drug SKYRIZI was included in the public drug formulary of Ontario and Alberta and received a conditional reimbursement recommendation from the Canadian drug agency. This progress demonstrates the company's ongoing efforts to expand patient access to innovative drugs, but the stock price still experienced a slight decline.
</li>
<li>
On May 2, market analysts maintained a moderate buy rating on AbbVie but did not include it in the top recommended stocks list. This rating may have affected investor confidence, leading to pressure on the stock price. The market remains optimistic about the long-term prospects of the pharmaceutical industry
</li>
</ol>

FATE

Fate Therap rose 23.61%; Cell Dynamics rose 20.39%, with a transaction volume of USD 683 million; Futu Pharma fell 1.80%, with a transaction volume of USD 233 million; Cellectar Biosciences rose 16.19%, with a transaction volume of USD 223 million; AbbVie fell 0.62%, with a market value of USD 365.9 billion

Price Alert

Fate Therap

U.S. stock market midday update: Fate Therapeutics rises 23.61%, driven by dual benefits from FDA projects and analyst ratings boosting stock price